Gut Microbiota Impairs Flutamide Efficacy in Prostate Cancer Treatment
Gut bacteria metabolize Flutamide into inactive forms, reducing its therapeutic efficacy against prostate cancer.
Company
Pharmaceutical intelligence for Bayer with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.